Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test: an independent quality assurance study.

Dabbs DJ, Klein ME, Mohsin SK, Tubbs RR, Shuai Y, Bhargava R.

J Clin Oncol. 2011 Nov 10;29(32):4279-85. doi: 10.1200/JCO.2011.34.7963. Epub 2011 Oct 11.

PMID:
21990395
2.

HER2 testing: state of the laboratories.

Mohsin SK.

Arch Pathol Lab Med. 2010 May;134(5):660-2. doi: 10.1043/1543-2165-134.5.660. No abstract available.

PMID:
20441496
3.

Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer.

Migliaccio I, Wu MF, Gutierrez C, Malorni L, Mohsin SK, Allred DC, Hilsenbeck SG, Osborne CK, Weiss H, Lee AV.

Breast Cancer Res Treat. 2010 Oct;123(3):651-60. doi: 10.1007/s10549-009-0632-6. Epub 2009 Nov 19.

4.

Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution.

Allred DC, Wu Y, Mao S, Nagtegaal ID, Lee S, Perou CM, Mohsin SK, O'Connell P, Tsimelzon A, Medina D.

Clin Cancer Res. 2008 Jan 15;14(2):370-8. doi: 10.1158/1078-0432.CCR-07-1127.

5.

Alterations of gene expression in the development of early hyperplastic precursors of breast cancer.

Lee S, Medina D, Tsimelzon A, Mohsin SK, Mao S, Wu Y, Allred DC.

Am J Pathol. 2007 Jul;171(1):252-62.

6.

Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer.

Massarweh S, Osborne CK, Jiang S, Wakeling AE, Rimawi M, Mohsin SK, Hilsenbeck S, Schiff R.

Cancer Res. 2006 Aug 15;66(16):8266-73.

7.

Interobserver reproducibility in the diagnosis of flat epithelial atypia of the breast.

O'Malley FP, Mohsin SK, Badve S, Bose S, Collins LC, Ennis M, Kleer CG, Pinder SE, Schnitt SJ.

Mod Pathol. 2006 Feb;19(2):172-9.

8.

Hormones, receptors, and growth in hyperplastic enlarged lobular units: early potential precursors of breast cancer.

Lee S, Mohsin SK, Mao S, Hilsenbeck SG, Medina D, Allred DC.

Breast Cancer Res. 2006;8(1):R6. Epub 2005 Dec 16.

9.

Morphologic and immunophenotypic markers as surrogate endpoints of tamoxifen effect for prevention of breast cancer.

Mohsin SK, Allred DC, Osborne CK, Cruz A, Otto P, Chew H, Clark GM, Elledge RM.

Breast Cancer Res Treat. 2005 Dec;94(3):205-11.

PMID:
16267611
10.

Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapies.

Martin MD, Hilsenbeck SG, Mohsin SK, Hopp TA, Clark GM, Osborne CK, Allred DC, O'Connell P.

Breast Cancer Res Treat. 2006 Jan;95(1):7-12. Epub 2005 Oct 22.

PMID:
16244788
11.

ER expression is not bimodal in breast cancer.

Allred DC, Mohsin SK.

Am J Clin Pathol. 2005 Sep;124(3):474-5; author reply 475-6. No abstract available.

PMID:
16196171
12.

Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience.

Dowsett M, Johnston S, Martin LA, Salter J, Hills M, Detre S, Gutierrez MC, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK, Smith I.

Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S113-7. Review.

PMID:
16113087
13.

Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIalpha for anthracycline chemotherapy in locally advanced breast cancer.

Arpino G, Ciocca DR, Weiss H, Allred DC, Daguerre P, Vargas-Roig L, Leuzzi M, Gago F, Elledge R, Mohsin SK.

Breast Cancer Res Treat. 2005 Jul;92(1):69-75.

PMID:
15980993
14.

Biomarker profile and genetic abnormalities in lobular carcinoma in situ.

Mohsin SK, O'Connell P, Allred DC, Libby AL.

Breast Cancer Res Treat. 2005 Apr;90(3):249-56.

PMID:
15830138
15.

Estrogen receptor positivity in mammary tumors of Wnt-1 transgenic mice is influenced by collaborating oncogenic mutations.

Zhang X, Podsypanina K, Huang S, Mohsin SK, Chamness GC, Hatsell S, Cowin P, Schiff R, Li Y.

Oncogene. 2005 Jun 16;24(26):4220-31.

PMID:
15824740
16.

Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase.

Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK, Dowsett M.

J Clin Oncol. 2005 Apr 10;23(11):2469-76. Epub 2005 Mar 7.

PMID:
15753463
17.

Neoadjuvant trastuzumab induces apoptosis in primary breast cancers.

Mohsin SK, Weiss HL, Gutierrez MC, Chamness GC, Schiff R, Digiovanna MP, Wang CX, Hilsenbeck SG, Osborne CK, Allred DC, Elledge R, Chang JC.

J Clin Oncol. 2005 Apr 10;23(11):2460-8. Epub 2005 Feb 14.

PMID:
15710948
18.

Decreased expression of e6-associated protein in breast and prostate carcinomas.

Gao X, Mohsin SK, Gatalica Z, Fu G, Sharma P, Nawaz Z.

Endocrinology. 2005 Apr;146(4):1707-12. Epub 2005 Feb 3.

PMID:
15691896
19.

Differences in breast cancer risk factors by tumor marker subtypes among premenopausal Vietnamese and Chinese women.

Nichols HB, Trentham-Dietz A, Love RR, Hampton JM, Hoang Anh PT, Allred DC, Mohsin SK, Newcomb PA.

Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):41-7.

20.

Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study.

Mohsin SK, Weiss H, Havighurst T, Clark GM, Berardo M, Roanh le D, To TV, Qian Z, Love RR, Allred DC.

Mod Pathol. 2004 Dec;17(12):1545-54. Erratum in: Mod Pathol. 2005 Mar;18(3):461. Qian, Zho [corrected to Qian, Zhang].

21.

Lobular neoplasia on core-needle biopsy--clinical significance.

Arpino G, Allred DC, Mohsin SK, Weiss HL, Conrow D, Elledge RM.

Cancer. 2004 Jul 15;101(2):242-50.

22.

Biological features of premalignant disease in the human breast.

Allred DC, Mohsin SK.

J Mammary Gland Biol Neoplasia. 2000 Oct;5(4):351-64. Review.

PMID:
14973381
23.

Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance.

Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK, Osborne CK.

Clin Cancer Res. 2004 Jan 1;10(1 Pt 2):331S-6S.

24.

Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors.

Lu C, Speers C, Zhang Y, Xu X, Hill J, Steinbis E, Celestino J, Shen Q, Kim H, Hilsenbeck S, Mohsin SK, Wakeling A, Osborne CK, Brown PH.

J Natl Cancer Inst. 2003 Dec 17;95(24):1825-33.

PMID:
14679152
25.

Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters.

Fuqua SA, Schiff R, Parra I, Moore JT, Mohsin SK, Osborne CK, Clark GM, Allred DC.

Cancer Res. 2003 May 15;63(10):2434-9.

26.

Maspin expression in invasive breast cancer: association with other prognostic factors.

Mohsin SK, Zhang M, Clark GM, Craig Allred D.

J Pathol. 2003 Apr;199(4):432-5.

PMID:
12635133
27.

Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer.

Love RR, Duc NB, Havighurst TC, Mohsin SK, Zhang Q, DeMets DL, Allred DC.

J Clin Oncol. 2003 Feb 1;21(3):453-7.

PMID:
12560434
28.

The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice.

Wu K, Zhang Y, Xu XC, Hill J, Celestino J, Kim HT, Mohsin SK, Hilsenbeck SG, Lamph WW, Bissonette R, Brown PH.

Cancer Res. 2002 Nov 15;62(22):6376-80.

30.

Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer.

Love RR, Duc NB, Allred DC, Binh NC, Dinh NV, Kha NN, Thuan TV, Mohsin SK, Roanh le D, Khang HX, Tran TL, Quy TT, Thuy NV, Thé PN, Cau TT, Tung ND, Huong DT, Quang le M, Hien NN, Thuong L, Shen TZ, Xin Y, Zhang Q, Havighurst TC, Yang YF, Hillner BE, DeMets DL.

J Clin Oncol. 2002 May 15;20(10):2559-66.

PMID:
12011136
31.

Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069.

Wu K, Kim HT, Rodriquez JL, Hilsenbeck SG, Mohsin SK, Xu XC, Lamph WW, Kuhn JG, Green JE, Brown PH.

Cancer Epidemiol Biomarkers Prev. 2002 May;11(5):467-74.

32.

Expression and localization of the CDC34 ubiquitin-conjugating enzyme in pediatric acute lymphoblastic leukemia.

Eliseeva E, Pati D, Diccinanni MB, Yu AL, Mohsin SK, Margolin JF, Plon SE.

Cell Growth Differ. 2001 Aug;12(8):427-33.

33.

Histological and biological evolution of human premalignant breast disease.

Allred DC, Mohsin SK, Fuqua SA.

Endocr Relat Cancer. 2001 Mar;8(1):47-61. Review.

PMID:
11350726
34.

Loss of heterozygosity events impeding breast cancer metastasis contain the MTA1 gene.

Martin MD, Fischbach K, Osborne CK, Mohsin SK, Allred DC, O'Connell P.

Cancer Res. 2001 May 1;61(9):3578-80.

35.

High rates of loss of heterozygosity on chromosome 19p13 in human breast cancer.

Oesterreich S, Allredl DC, Mohsin SK, Zhang Q, Wong H, Lee AV, Osborne CK, O'Connell P.

Br J Cancer. 2001 Feb;84(4):493-8.

36.

9-cis-Retinoic acid suppresses mammary tumorigenesis in C3(1)-simian virus 40 T antigen-transgenic mice.

Wu K, Kim HT, Rodriquez JL, Munoz-Medellin D, Mohsin SK, Hilsenbeck SG, Lamph WW, Gottardis MM, Shirley MA, Kuhn JG, Green JE, Brown PH.

Clin Cancer Res. 2000 Sep;6(9):3696-704.

37.

Loss of heterozygosity at D14S62 and metastatic potential of breast cancer.

O'Connell P, Fischbach K, Hilsenbeck S, Mohsin SK, Fuqua SA, Clark GM, Osborne CK, Allred DC.

J Natl Cancer Inst. 1999 Aug 18;91(16):1391-7.

PMID:
10451444
38.

Cutaneous verruciform xanthoma: a report of five cases investigating the etiology and nature of xanthomatous cells.

Mohsin SK, Lee MW, Amin MB, Stoler MH, Eyzaguirre E, Ma CK, Zarbo RJ.

Am J Surg Pathol. 1998 Apr;22(4):479-87.

PMID:
9537477

Supplemental Content

Loading ...
Support Center